Ocular Therapeutix, Inc. (NASDAQ:OCUL) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $4.66 and last traded at $4.97, with a volume of 218500 shares. The stock had previously closed at $5.04.

A number of research firms have weighed in on OCUL. ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. HC Wainwright started coverage on Ocular Therapeutix in a report on Wednesday, July 26th. They set a “buy” rating and a $10.00 price objective for the company. BTIG Research reissued a “neutral” rating on shares of Ocular Therapeutix in a report on Thursday, August 10th. Cantor Fitzgerald reissued a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Monday, September 25th. Finally, Guggenheim started coverage on Ocular Therapeutix in a report on Monday, October 23rd. They set a “buy” rating and a $12.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company’s stock. Ocular Therapeutix has a consensus rating of “Hold” and an average price target of $20.67.

The company has a current ratio of 4.79, a quick ratio of 4.78 and a debt-to-equity ratio of 0.39.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.54). Ocular Therapeutix had a negative return on equity of 126.31% and a negative net margin of 3,241.19%. The company had revenue of $523.00 million during the quarter, compared to analyst estimates of $0.52 million. During the same period in the previous year, the company earned ($0.39) EPS. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. research analysts predict that Ocular Therapeutix, Inc. will post -2.37 EPS for the current fiscal year.

In other news, Chairman Amarpreet Sawhney bought 19,000 shares of the business’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average price of $5.18 per share, for a total transaction of $98,420.00. Following the purchase, the chairman now owns 696,390 shares of the company’s stock, valued at approximately $3,607,300.20. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 26.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Voya Investment Management LLC bought a new stake in shares of Ocular Therapeutix during the 2nd quarter worth approximately $102,000. American International Group Inc. raised its stake in Ocular Therapeutix by 8.2% in the 1st quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 844 shares during the period. Nationwide Fund Advisors raised its stake in Ocular Therapeutix by 10.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,344 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,204 shares during the period. State of Wisconsin Investment Board bought a new stake in Ocular Therapeutix in the 2nd quarter valued at $167,000. Finally, New York State Common Retirement Fund raised its stake in Ocular Therapeutix by 45.3% in the 2nd quarter. New York State Common Retirement Fund now owns 18,600 shares of the biopharmaceutical company’s stock valued at $172,000 after acquiring an additional 5,799 shares during the period. Hedge funds and other institutional investors own 53.97% of the company’s stock.

WARNING: This piece was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/11/20/ocular-therapeutix-inc-ocul-sets-new-52-week-low-at-4-66.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery.

Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.